Eli Lilly and Company (NYSE:LLY) PT Raised to $865.00

Eli Lilly and Company (NYSE:LLYGet Free Report) had its price objective upped by investment analysts at BMO Capital Markets from $710.00 to $865.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. BMO Capital Markets’ target price points to a potential upside of 17.60% from the stock’s current price.

Several other analysts have also commented on LLY. Cantor Fitzgerald reiterated an “overweight” rating and issued a $630.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 1st. Deutsche Bank Aktiengesellschaft started coverage on Eli Lilly and Company in a research note on Thursday, November 9th. They issued a “hold” rating and a $535.00 target price for the company. Citigroup increased their price target on shares of Eli Lilly and Company from $525.00 to $675.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, November 3rd. Finally, Barclays lifted their target price on shares of Eli Lilly and Company from $630.00 to $680.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $621.81.

Read Our Latest Analysis on LLY

Eli Lilly and Company Stock Up 1.4 %

LLY stock opened at $735.56 on Wednesday. The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 1.59. The company’s 50-day moving average price is $616.90 and its 200 day moving average price is $578.22. Eli Lilly and Company has a 52 week low of $309.20 and a 52 week high of $742.00. The company has a market cap of $698.27 billion, a P/E ratio of 126.82, a P/E/G ratio of 2.24 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 50.78% and a net margin of 15.36%. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter last year, the business posted $2.09 earnings per share. On average, research analysts expect that Eli Lilly and Company will post 12.73 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 1,180 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $645.60, for a total value of $761,808.00. Following the sale, the insider now owns 99,542,630 shares of the company’s stock, valued at approximately $64,264,721,928. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders have sold 195,055 shares of company stock worth $125,254,657. Insiders own 0.13% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at about $27,000. Retirement Group LLC increased its position in Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after acquiring an additional 35 shares in the last quarter. Cornerstone Planning Group LLC bought a new position in shares of Eli Lilly and Company in the second quarter worth about $33,000. Finally, Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company during the third quarter worth approximately $35,000. Institutional investors own 81.38% of the company’s stock.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.